Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Ho

Showing results (131-140 of 192) with videos related to

Pageof 20
Sort By:
Psychiatry Research|December 10, 2021
Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellenceJoshua D Di Vincenzo, Orly Lipsitz, Nelson B Rodrigues, et al.
Expert Opinion on Drug Safety|April 15, 2022
Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention, and treatmentMarcus A Doyle, Susan Ling, Leanna M W Lui, et al.
Current Medical Research and Opinion|July 2, 2024
Relationship between anhedonia and psychosocial functioning in post-COVID-19 condition: a <i>post-hoc</i> analysisSonya Liao, Kayla M Teopiz, Angela T H Kwan, et al.
CNS Spectrums|May 26, 2025
Should glutamatergic modulators be considered preferential treatments for adults with major depressive disorder and a reported history of trauma? Conceptual and clinical implicationsKayla M Teopiz, Heidi K Y Lo, Moiz Lakhani, et al.
Journal of Affective Disorders|October 17, 2025
Effects of glutamatergic modulators on striatal activation, functional connectivity and reward in persons with major depressive disorder and healthy controls: A systematic review of fMRI studiesKayla M Teopiz, Sabrina Wong, Gia Han Le, et al.
Journal of Affective Disorders|February 1, 2026
The effect of glucagon-like peptide 1 (GLP-1) receptor agonists on cognition: A systematic review of systematic reviews and meta-analysesHana Ballum, Christine Dri, Sonya Liao, et al.
Journal of Affective Disorders|January 10, 2021
Insulin resistance is associated with deficits in hedonic, self-reported cognitive, and psychosocial functional response to antidepressant treatment in individuals with major depressive disorderHouman Rashidian, Mehala Subramaniapillai, Caroline Park, et al.
Psychiatry Research|May 25, 2021
The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE)Roger S McIntyre, Joshua D Rosenblat, Nelson B Rodrigues, et al.
CNS Spectrums|December 10, 2020
Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulationNelson B Rodrigues, Ashley Siegel, Orly Lipsitz, et al.
European Archives of Psychiatry and Clinical Neuroscience|September 22, 2024
Correction: Subjective and objective measures of cognitive function are correlated in persons with Post-COVID-19 Condition: a secondary analysis of a Randomized Controlled TrialAngela T H Kwan, Moiz Lakhani, Gia Han Le, et al.
Pageof 20

Showing results (131-140 of 192) with videos related to

Sort By:
Pageof 20
Psychiatry Research|December 10, 2021
Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellenceJoshua D Di Vincenzo, Orly Lipsitz, Nelson B Rodrigues, et al.
Expert Opinion on Drug Safety|April 15, 2022
Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention, and treatmentMarcus A Doyle, Susan Ling, Leanna M W Lui, et al.
Current Medical Research and Opinion|July 2, 2024
Relationship between anhedonia and psychosocial functioning in post-COVID-19 condition: a <i>post-hoc</i> analysisSonya Liao, Kayla M Teopiz, Angela T H Kwan, et al.
CNS Spectrums|May 26, 2025
Should glutamatergic modulators be considered preferential treatments for adults with major depressive disorder and a reported history of trauma? Conceptual and clinical implicationsKayla M Teopiz, Heidi K Y Lo, Moiz Lakhani, et al.
Journal of Affective Disorders|October 17, 2025
Effects of glutamatergic modulators on striatal activation, functional connectivity and reward in persons with major depressive disorder and healthy controls: A systematic review of fMRI studiesKayla M Teopiz, Sabrina Wong, Gia Han Le, et al.
Journal of Affective Disorders|February 1, 2026
The effect of glucagon-like peptide 1 (GLP-1) receptor agonists on cognition: A systematic review of systematic reviews and meta-analysesHana Ballum, Christine Dri, Sonya Liao, et al.
Journal of Affective Disorders|January 10, 2021
Insulin resistance is associated with deficits in hedonic, self-reported cognitive, and psychosocial functional response to antidepressant treatment in individuals with major depressive disorderHouman Rashidian, Mehala Subramaniapillai, Caroline Park, et al.
Psychiatry Research|May 25, 2021
The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE)Roger S McIntyre, Joshua D Rosenblat, Nelson B Rodrigues, et al.
CNS Spectrums|December 10, 2020
Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulationNelson B Rodrigues, Ashley Siegel, Orly Lipsitz, et al.
European Archives of Psychiatry and Clinical Neuroscience|September 22, 2024
Correction: Subjective and objective measures of cognitive function are correlated in persons with Post-COVID-19 Condition: a secondary analysis of a Randomized Controlled TrialAngela T H Kwan, Moiz Lakhani, Gia Han Le, et al.
Pageof 20